SDAX

EQS-News: Mutares has successfully completed the acquisition of Temakinho from Cigierre S.p.A., controlled by BC Partners

Retrieved on: 
Wednesday, March 13, 2024
Acquisition, Restaurant, Supervisory board, HQ, MUX, Retail, BC Partners, EUR, Regulated market, SDAX, Frankfurt Stock Exchange, Shipbuilding

Mutares has successfully completed the acquisition of Temakinho from Cigierre S.p.A., controlled by BC Partners

Key Points: 
  • Mutares has successfully completed the acquisition of Temakinho from Cigierre S.p.A., controlled by BC Partners
    The issuer is solely responsible for the content of this announcement.
  • Mutares has successfully completed the acquisition of Temakinho from Cigierre S.p.A., controlled by BC Partners
    Munich, March 1, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully completed the acquisition of Temakinho S.r.l.
  • ("Temakinho") from Cigierre – Compagnia Generale Ristorazione S.p.A. ("Cigierre"), owned by funds advised by BC Partners.
  • Temakinho has access to a central kitchen near Milan, where selected ingredients are processed and semi-finished products are temporarily stored and then delivered.

EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan

Retrieved on: 
Wednesday, March 13, 2024
Neoplasm, NEN, PMDA, Patient, Clinical trial, SDAX, PET, Medical imaging

Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.

Key Points: 
  • Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.
  • (Japan).
  • For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm® as the single source for Ga-68.
  • “We are happy to extend our radioisotope supply business in Japan by contributing our GalliaPharm® to this important clinical research project,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler AG.

EQS-News: Mutares has successfully sold its portfolio company Frigoscandia to Dachser

Retrieved on: 
Wednesday, March 13, 2024
Acquisition, Supervisory board, HQ, MUX, Mutares, EUR, Regulated market, SDAX, GKT, Frankfurt Stock Exchange, Film industry

Munich, March 4, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully sold its portfolio company Frigoscandia to Dachser, a global leader in groupage logistics.

Key Points: 
  • Munich, March 4, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully sold its portfolio company Frigoscandia to Dachser, a global leader in groupage logistics.
  • Headquartered in Helsingborg, Sweden, Frigoscandia is a full-service provider of temperature-controlled logistics in the Nordic market.
  • With around 1,300 people the company generated more than EUR 300 million in revenues in 2023.
  • As the portfolio grows, so do consulting revenues, which together with portfolio dividends and exit proceeds accrue to the Mutares Holding.

EQS-News: First acquisition in 2024: Mutares has signed an agreement to acquire Temakinho from Cigierre S.p.A., controlled by BC Partners

Retrieved on: 
Friday, February 16, 2024
Acquisition, Restaurant, Supervisory board, HQ, MUX, Retail, Meat, BC Partners, EUR, DOS, Regulated market, SDAX, Frankfurt Stock Exchange, Property management

First acquisition in 2024: Mutares has signed an agreement to acquire Temakinho from Cigierre S.p.A., controlled by BC Partners

Key Points: 
  • First acquisition in 2024: Mutares has signed an agreement to acquire Temakinho from Cigierre S.p.A., controlled by BC Partners
    The issuer is solely responsible for the content of this announcement.
  • First acquisition in 2024: Mutares has signed an agreement to acquire Temakinho from Cigierre S.p.A., controlled by BC Partners
    Munich, February 16, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has signed an agreement to acquire Temakinho S.r.l.
  • ("Temakinho") from Cigierre – Compagnia Generale Ristorazione S.p.A. ("Cigierre"), owned by funds advised by BC Partners.
  • Founded in 2012 and headquartered in Milan, Temakinho has been the Italian pioneer offering premium Japanese-Brazilian sushi, meat cuisine and drinks.

EQS-News: CEWE again significantly increases turnover and earnings in 2023

Retrieved on: 
Wednesday, February 14, 2024
Online, Economic development, Marketing, Growth, Communication, Commercial, SDAX

Oldenburg, February 14, 2024 - CEWE Stiftung & Co. KGaA (SDAX, ISIN: DE 0005403901) closed the 2023 financial year with a significant increase in turnover and earnings according to preliminary, unaudited figures: Group turnover, including futalis, which was sold in December 2023, increased by +6.5% to 788.8 million euros (2022: 741.0 million euros), while the CEWE Group's operating result (EBIT) calculated in this way rose to 81.6 million euros (2022: 75.6 million euros).

Key Points: 
  • Oldenburg, February 14, 2024 - CEWE Stiftung & Co. KGaA (SDAX, ISIN: DE 0005403901) closed the 2023 financial year with a significant increase in turnover and earnings according to preliminary, unaudited figures: Group turnover, including futalis, which was sold in December 2023, increased by +6.5% to 788.8 million euros (2022: 741.0 million euros), while the CEWE Group's operating result (EBIT) calculated in this way rose to 81.6 million euros (2022: 75.6 million euros).
  • CEWE had planned Group turnover in the target range of 720 to 780 million euros and EBIT of up to 82 million euros for 2023.
  • Group EBIT improved by 4.6 million euros or 5.9% to 81.6 million euros (EBIT Q4 2022: 77.0 million euros).
  • According to preliminary calculations, both the Commercial Online-Print and Retail business segments closed the 2023 financial year with a significantly improved result.

EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Monday, February 5, 2024
Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.

EQS-News: Parity still a long way off / FidAR Forum 2024 calls for substantial progress in increasing the proportion of women in management positions in Germany

Retrieved on: 
Monday, February 5, 2024
Supervisory board, SAP, Financial services, CFO, Hannover Re, DAX, Regulated market, ESMT, Sustainability, Old age, SDAX, Labour, Parity, Commerzbank, Salzgitter, MDAX, Bechtle, Management, Zalando, Federation, Hope, Siemens Healthineers, European School, Woman, BASF, Property management

Berlin, 31.01.2024: DAX companies are leading the way when it comes to equal participation of women in Germany.

Key Points: 
  • Berlin, 31.01.2024: DAX companies are leading the way when it comes to equal participation of women in Germany.
  • On the supervisory boards, the proportion of women is still just below the 40 per cent mark at 38.5 per cent.
  • Six supervisory boards at Hannover Re, Zalando, Commerzbank, Covestro, Heidelberg Materials and Vonovia have at least equal representation of women and men.
  • Substantial progress requires concrete strategies for sustainably increasing the proportion of women at all management levels.

Eckert & Ziegler to Supply Nucleus RadioPharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Wednesday, January 31, 2024
Research, Genetics, Health Technology, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply, and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.

EQS-News: SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory

Retrieved on: 
Tuesday, January 30, 2024
DAX, Drug, Diabetes, Obesity, Patient, Frankfurt Stock Exchange, HVS, Glass, Syringe, CFO, DDS, SCHOTT, DCS, Annual, Cancer, Administration, Parkinson's disease, Insulin, Spacecraft, Supervisory board, Investment, SDAX, IPO, EUR, FY, Messenger, Growth, Fine chemical

“With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.

Key Points: 
  • “With our 2023 results, we have delivered on all our targets and have proven that SCHOTT Pharma is a highly profitable business.
  • We will continue to benefit from key pharma trends and the overall market growth for injectable drugs”, said Almuth Steinkühler, CFO of SCHOTT Pharma.
  • In 2023, SCHOTT Pharma continued to deliver on its strategy and achieved several milestones along the pillars expansion and innovation.
  • On the innovation side, SCHOTT Pharma successfully introduced two leading innovations to the market that serve the pharma megatrends Glucagon-like peptide-1 (GLP-1) and mRNA.

EQS-News: Mutares places second tap issue of its bond issued in March 2023 with a volume of EUR 100 million and strengthens basis for further development

Retrieved on: 
Tuesday, January 30, 2024
HQ, Frankfurt Stock Exchange, Noerr, Regulated market, Supervisory board, SDAX, Finance Secretary (India), Acquisition, MUX, EUR, Film industry

Munich, January 19, 2024 – Today, Mutares SE & Co. KGaA (ISIN: DE000A2NB650) ("Mutares") has decided to increase its EUR 100 million bond issued in March 2023 with maturity on 31 March 2027 (ISIN: NO0012530965) and tapped by EUR 50 million in May 2023 ("Bond") through an optional Tap Issue by an amount of EUR 100 million ("Tap Issue").

Key Points: 
  • Munich, January 19, 2024 – Today, Mutares SE & Co. KGaA (ISIN: DE000A2NB650) ("Mutares") has decided to increase its EUR 100 million bond issued in March 2023 with maturity on 31 March 2027 (ISIN: NO0012530965) and tapped by EUR 50 million in May 2023 ("Bond") through an optional Tap Issue by an amount of EUR 100 million ("Tap Issue").
  • The Management Board of Mutares had decided to further increase the bond, given the opportunities on the buy-side and optimal market conditions.
  • The strategic move is based on Mutares' excellent positioning with a very robust and attractive pipeline in all regions.
  • The net proceeds from the tap issue will enable Mutares to take maximum advantage of the opportunities that arise on the buy-side.